At Dynacare, our vision is to be Canada’s health and wellness solutions leader. On June 1, 2021, Dynacare will be making changes to SARS-CoV-2 (COVID-19) Antibody testing for non-travel purposes; SARS-CoV-2 (COVID-19) Antibody testing for travel eligibility will not be changing.
To date, Dynacare has offered two separate SARS-CoV-2 Antibody tests for non-travel purposes: SARS-CoV-2 Nucleocapsid Antibody and SARS-CoV-2 Spike Total Antibody. For SARS-CoV-2 Nucleocapsid Antibody testing, Dynacare performed a two-step algorithm, whereby samples positive for Nucleocapsid Total Antibody were subsequently tested with a Nucleocapsid IgG Antibody assay. The rationale for this testing strategy was to minimize false-positive results associated with low prevalence of SARS-CoV-2.
Read More - Partner Update